TSX runs higher on rate cut expectations
WEST CHESTER, Penn. - Johnson & Johnson MedTech (NYSE:JNJ) on Tuesday announced the launch of its VIRTUGUIDEâ„¢ System, an AI-powered solution designed to support Lapidus procedures for bunion correction.
The system, which received FDA 510(k) clearance earlier this year, uses pre-operative planning software developed with PeekMed® to assess each patient’s condition and make personalized recommendations for surgical correction.
According to the company, early adopters of the technology reported procedural time savings of approximately 30 minutes compared to traditional techniques. The system aims to reduce surgical complexity for Lapidus procedures, which realign the foot by joining two bones near the arch.
Bunions affect nearly one-third of adults in the United States, the company noted in its press release.
"This milestone marks an important step forward, as VIRTUGUIDEâ„¢ becomes the latest addition to our growing portfolio of VELYSâ„¢ Enabling Tech solutions," said Oray Boston, Worldwide President of Trauma, Extremities, Craniomaxillofacial, Animal Health and Sports Medicine, Orthopaedics at Johnson & Johnson MedTech.
The system is now available in the U.S. market, joining Johnson & Johnson’s orthopaedic solutions portfolio that addresses joint reconstruction, spine, sports, trauma, and extremities.
Dr. Michael Campbell, a board-certified orthopaedic surgeon at Atlantic Orthopaedic Specialists and paid consultant for Johnson & Johnson MedTech, stated that the system has transformed his approach to bunion surgery by making the procedure easier and faster.
In other recent news, Johnson & Johnson has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Tremfya, seeking to update the label with new evidence on inhibiting structural damage progression in adults with active psoriatic arthritis. This submission is backed by results from the Phase 3b APEX study, which showed significant improvements in joint symptoms and structural damage inhibition compared to a placebo. Additionally, Johnson & Johnson has applied for FDA approval for icotrokinra, a new oral peptide for moderate to severe plaque psoriasis, based on successful outcomes from four Phase 3 clinical trials. In Europe, the company’s Darzalex subcutaneous formulation has received approval from the European Commission for use in adults with high-risk smoldering multiple myeloma, marking a first for this patient group. Meanwhile, Erste Group has upgraded Johnson & Johnson’s stock rating from Hold to Buy, highlighting the company’s superior operating margin and return on equity compared to its peers. RBC Capital has also raised its price target for Johnson & Johnson to $185, citing the company’s better-than-expected second-quarter sales and earnings per share. These developments reflect ongoing advancements and favorable evaluations for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.